Covaxin booster dose safe, says Bharat Biotech
Advertisement
New Delhi: Covaxin manufacturer Bharat Biotech on Saturday said that the booster dose trials have shown "promising results" of long-term safety with "no serious adverse events".
The Hyderabad-based company announced the results on the safety and immunogenicity of COVAXIN (BBV152), a whole-virion inactivated COVID-19 vaccine as a booster dose.
"Covaxin trial demonstrated long-term safety with no serious adverse events. 90 per cent of recipients had a detectable neutralizing antibody response against the wild-type strain (six months after the second dose)," Bharat Biotech said in an official statement.
The frequency of adverse events was found to be lower than vaccines from other manufacturing platforms, it added.
Six months after receiving the second dose, the participants received a third booster dose.
"Neutralization titers against wild-type and Delta variants were five times higher than after a two-dose schedule," the firm said.
The analysis showed, six months after a two-dose BBV152 vaccination series cell-mediated immunity and neutralizing antibodies to both homologous (D614G) and heterologous strains (Alpha, Beta, Delta, and Delta plus) persisted above baseline, although the magnitude of the responses had declined.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.